Creative Proteomics Logo

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

Drug–Drug Interaction (DDI) Screening Services for Early Drug Discovery

In vitro drug–drug interaction (DDI) assessment is essential for identifying metabolic liabilities and safety risks before lead compounds advance to the clinic. Creative Proteomics DMPK provides customized, high-throughput DDI screening services tailored for biotech R&D and academic research.

De Novo Assay Development

Expert design of customized protocols for proprietary structures where standard kits fail.

High-Throughput Screening

Infrastructural capacity to process libraries of hundreds to thousands of compounds with stable consistency.

ISO 17025 Traceability

All data generated within a certified quality management system, ensuring unparalleled analytical precision.

REQUEST A DDI ASSAY CONSULT
DDI Complexity Precision Workflow Assay Menu Demo Results Technical Strengths Sample Requirements Related Service Case Study FAQ

Navigating the Complexity of In Vitro DDI Evaluation

Transitioning a promising lead into a viable candidate requires understanding how it modulates the metabolic pathways of co-administered drugs. Integrating specialized metabolite quantification services ensures precise exposure tracking, as unique physicochemical properties like extreme lipophilicity (LogP) or high non-specific binding can lead to inaccurate potency estimates in standardized assays.

Our platform addresses these challenges through inquiry-driven custom delivery. We utilize high-resolution mass spectrometry (HRMS) to ensure absolute molecular specificity and baseline stability, providing high-sensitivity data for subsequent pharmacokinetic modeling.

Precision DDI Workflow & QC Checkpoints

Our workflow incorporates stringent quality control at every critical juncture to ensure reproducible data delivery for discovery-stage projects.

  1. Scientific Consultation: Inquiry-driven selection of in vitro models and inhibitor concentration ranges.
  2. De Novo Method Optimization: Deploying specialized custom LC-MS/MS method development protocols to achieve baseline separation from interfering matrix signals.
  3. High-Throughput Execution: Automated 96/384-well processing utilizing Triple Quadrupole (QQQ) mass spectrometry, with options to bridge into advanced drug metabolite identification (MetID) streams when unknown biotransformations disrupt screening metrics.
  4. Kinetic Data Modeling: Precision calculation of IC50, Ki, and TDI parameters using validated software.

Horizontal Workflow for DDI Screening Pipeline

Comprehensive DDI Assay Menu

Assay Category Biological Models Parameters Measured Strategic Value
CYP Inhibition HLM, S9, Recombinant Enzymes IC50, Ki, Kinact Leveraging a pre-validated CYP inhibition assay framework to detect reversible and mechanism-based (TDI) inhibition.
CYP Induction Primary Hepatocytes mRNA, Enzyme activity Assesses risk of accelerated clearance via Emax/EC50.
Transporter DDI Caco-2, Transfected Cells Efflux Ratio, IC50 Evaluates "Big 7" (P-gp, BCRP, OATP, etc.) interactions.
Reaction Phenotyping HLM, Recombinant CYPs Fraction metabolized (fm) Identifies specific enzymes responsible for NCE clearance.
Metabolic Stability HLM, Hepatocytes, Blood T1/2, CLint Determines intrinsic clearance and half-life in discovery.

High-Resolution Demo Results Showcase

Our data packages include the quantitative metrics required to verify the success of complex metabolic studies:

  • Seven-Point IC50 Profiles: Non-linear regression plots for all major CYP isoforms.
  • TDI Shift Curves: Comparison of values with and without pre-incubation to identify irreversible inactivation.
  • mRNA Induction Histograms: Bar charts showing fold-induction levels calibrated against positive controls.
  • Representative MRM Chromatograms: Visual proof of sensitivity and baseline separation in complex matrices.
  • Transporter Efflux Ratios: Quantitative transport kinetics across polarized cell monolayers.
  • fm Breakdown: Graphical pie charts identifying the metabolic contribution of individual enzymes.
IC50 Regression Curve Demo
TDI Shift Analysis Plot
High-Resolution MRM Chromatogram

Technical Strengths: The ISO 17025 Advantage

Dimension ISO 17025 LC-MS/MS Platform Standard Generic Kits / ELISA
Analytical Specificity Absolute identification via exact m/z transitions; no cross-reactivity. High risk of false positives from metabolites or background.
Platform Customization Adaptable for novel structures and proprietary enzyme targets. Restricted to pre-fixed targets; no discovery flexibility.
Matrix Mitigation Controlled via de novo extraction (SPE/LLE) to eliminate ion suppression. Highly susceptible to signal quenching in complex tissues.
Data Integrity Fully traceable data with rigorous precision documentation. Minimal scientific documentation or mechanistic insight.

Sample Submission Requirements

Requirement Specification Notes
Compound Form Solid or 10 mM DMSO stock Solid is preferred for discovery NCE stability.
Quantity 5 – 10 mg (Solid) Minimum 2 mg for pilot DDI studies.
Purity > 95% (recommended) Lower purity may require de novo method adjustment.
Logistics Dry Ice / Global Tracking Support for cross-border sample shipping and compliance.

Explore Related Bioanalytical Services

Comprehensive early discovery research requires checking compounds across multiple distinct metabolic compartments. Expand your preclinical evaluation strategy by exploring our integrated, specialized capabilities:

Case Study: High-Sensitivity LC-MS/MS Screening for Transporter-Mediated DDI

Background

Evaluating transporter-mediated drug interactions is a critical regulatory requirement for novel chemical entities (NCEs). A project required the precise quantification of organic cation transporter (OCT) uptake and its inhibition by novel compounds in cellular models to assess clearance risks.

Methods

An inquiry-driven UPLC-MS/MS assay was developed to quantify probe substrates in cell lysates. The de novo method utilized a highly optimized extraction procedure, ensuring near 100% recovery and eliminating severe matrix effects caused by intracellular proteins and lipids.

Results

The method successfully quantified intracellular accumulation at sub-nanogram levels, identifying potent transporter inhibitors among the test compounds. For definitive visual verification of the analytical precision and calibration robustness achieved in similar DDI transporter research, please refer to the peer-reviewed study: A Highly Sensitive UPLC-MS/MS Method for the Quantification of the Organic Cation Transporters' Mediated Metformin Uptake and Its Inhibition in Cells.

Conclusion

This study enabled the client to accurately assess transporter-mediated DDI risks, optimizing early-stage lead selection and avoiding late-stage clinical attrition.

Transporter Inhibition IC50 Curve from MDPI 2024

Bioinformatics and Data Modeling

  • Mechanistic Modeling: Determination of Ki values for competitive and non-competitive inhibition.
  • PBPK Model Readiness: Data delivery in standardized formats ready for physiologically based pharmacokinetic modeling.
  • Statistical Significance: Rigorous data normalization for mRNA induction studies, accounting for biological variability.

Frequently Asked Questions

Can you develop a DDI assay for specific Phase II enzymes?

Yes. We design customized LC-MS/MS assays for UGT isoforms (e.g., 1A1, 2B7) using recombinant enzymes and specialized co-factors.

How do you handle compounds with low solubility?

We utilize low-protein binding plasticware and optimize incubation parameters (e.g., microsome concentration) to ensure accurate IC50 determination.

Do you provide guidance on transporter screening?

Yes. We typically recommend the "Big 7" transporters (P-gp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, and OCT2) to cover common early discovery risks.

What is the difference between IC50 shift and full Kinact/KI?

An IC50 shift is a rapid screening tool used to flag potential time-dependent inhibitors; full Kinact/KI studies provide the absolute constants required for in-depth risk modeling.

References

  1. In Vitro Drug-Drug Interaction Studies (FDA Scientific Guidance)
  2. A Highly Sensitive UPLC-MS/MS Method for the Quantification of the Organic Cation Transporters' Mediated Metformin Uptake and Its Inhibition in Cells (Molecules, 2024)
  3. Strategies for assessing time-dependent inhibition in early drug discovery (2024)

Ready to Quantify Your Lead Compound or Metabolite?

Share your matrix type, sample count, and expected range—feasibility routing will confirm whether direct quantification is fit-for-purpose or method development is recommended.

Want to browse compounds, matrices, and assay coverage? Explore the Library →

inquiry

For research purposes only, not intended for clinical diagnosis, treatment, or individual health assessments.

Online Inquiry
Quick Links

Home

Service

Library

Resource

About Us

Contact Us

USA

Tel:

Fax:

Email:

Germany

Copyright © 2026 Creative Proteomics. All rights reserved.